Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer.